Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

Inclusion Criteria:

• Subject must be ≥18 years of age.

• Subject must have pathologically documented, locally advanced or metastaticKRASG12C-mutated solid tumor malignancy (not amenable to curative surgery) that haspreviously been treated with standard-of-care therapies for respective tumor types,is intolerant to, or is considered ineligible for standard-of-care anticancertreatments.

• ECOG performance status 0 or 1

• Prior treatment with a KRASG12C (OFF) inhibitor allowed for dose escalation and forNSCLC in dose expansion

• Adequate organ function

Exclusion Criteria:

• Primary central nervous system (CNS) tumors

• Active brain metastases

• Known impairment of GI function that would alter the absorption

• Major surgical procedures within 28 days or non-study-related minor procedureswithin 7 days of treatment.

• Prior therapy with KRASG12C (ON) inhibitor

Other inclusion/exclusion criteria may apply.